Business Context and Reporting Period
Company: Evotec SE (Evotec AG)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Periods:
- Full Year Ended December 31, 2009
- First Quarter Ended March 31, 2010
Key Financial Metrics
Full Year 2009 Results
| Metric | 2009 | 2008 | Change |
|---|---|---|---|
| Revenues | EUR 42.7 million | EUR 39.6 million | +8% |
| Operating Loss (before exceptional items) | EUR 19.6 million | EUR 45.5 million | -57% (Improvement) |
| Operating Loss (including impairments/restructuring) | EUR 42.3 million | EUR 73.2 million | -42% (Improvement) |
| Net Loss | EUR 45.5 million | EUR 78.3 million | -42% (Improvement) |
| R&D Expenses | EUR 20.9 million | EUR 42.5 million | -51% |
| SG&A Expenses | EUR 16.7 million | EUR 20.0 million | -16% |
| Liquidity (Cash, Investments, ARS) | EUR 70.6 million | EUR 92.4 million | -24% |
| Impairment Charges | EUR 18.2 million | EUR 28.1 million | -35% |
First Quarter 2010 Results
| Metric | Q1 2010 | Q1 2009 | Change |
|---|---|---|---|
| Revenues | EUR 9.8 million | EUR 8.2 million | +19% |
| Gross Margin | 37.9% | 36.2% | +1.7 pts |
| Operating Loss | EUR 1.5 million | EUR 20.2 million | -93% (Improvement) |
| Net Loss | EUR 1.2 million | EUR 21.8 million | -94% (Improvement) |
| R&D Expenses | EUR 1.7 million | EUR 10.3 million | -83% |
| SG&A Expenses | EUR 3.4 million | EUR 4.8 million | -30% |
| Liquidity (as of March 31, 2010) | EUR 66.8 million | EUR 70.6 million (Dec 31, 2009) | -5.4% |
Material Changes vs. Prior Period
- Revenue Growth: Driven by strong performance in discovery alliances and the recognition of upfront payments from the Roche partnership. Q1 2010 revenue growth of 19% occurred without milestone payments, indicating organic growth in service revenues.
- Cost Reduction: Significant reduction in R&D expenses (down 51% in 2009, 83% in Q1 2010) due to the closure of the US facility (Renovis), headcount reductions, and the shift of EVT 100 development costs to Roche. SG&A expenses also declined significantly due to restructuring.
- Impairments: In 2009, the company recorded EUR 18.2 million in impairment charges for higher-risk programs (EVT 201, EVT 401, VR1) to align with its de-risked strategy. Q1 2010 had no impairment charges.
- Profitability Trend: The company achieved a positive operating result before exceptional items in Q4 2009 (EUR 2.0 million) and significantly reduced the operating loss in Q1 2010 to EUR 1.5 million.
Guidance, Outlook, and Management Commentary
2010 Guidance (Confirmed May 2010)
- Revenue: Expected to grow by at least 15% (excluding out-licensing income), based on a strong order book of approximately EUR 30 million as of March 2010.
- Operating Result: Expected to improve significantly over 2009 before impairment charges.
- R&D Expenses: Expected to be approximately EUR 10 million for the full year 2010.
- Liquidity: Expected to end 2010 with liquidity greater than EUR 64 million (at constant year-end 2009 currencies).
- Profitability: Management targets profitability no later than 2012.
Strategic Highlights
- Discovery Alliances: New multi-year alliance with Genentech (announced May 2010) and extension of the CHDI collaboration (Huntington's disease) for three years (up to USD 37.5 million funding).
- Roche Partnership: Costs for EVT 101 (Phase II) and EVT 103 (Phase I) are fully borne by Roche. FDA approval received to initiate Phase II for EVT 101 in Q2 2010. Potential buy-back payment of USD 65 million upon Phase II completion.
- Acquisitions: Acquisition of RSIPL (India) in August 2009 expanded capacity and cost efficiency. Acquisition of zebrafish screening operations from Summit Corporation.
- Restructuring: Closure of South San Francisco facility and concentration of operations in Europe and Asia.
Risks and Contingencies
- Clinical Development: Risks associated with the failure of proprietary drug candidates (e.g., EVT 302 failed in smoking cessation trials) and regulatory hurdles (FDA requirements).
- Market Dependence: Reliance on a few large customers (two largest customers represented >40% of 2009 revenues).
- Liquidity: Holdings in auction rate securities (ARS) which have faced liquidity issues in the market, though secured by bank repurchase warranties.
- Integration: Risks related to the integration of acquired entities (RSIPL, Summit) and achieving anticipated synergies.
Key Facts for Investor Verification
- Liquidity Runway: Verify the company's ability to maintain liquidity above EUR 64 million through 2010 given the cash burn rate and reliance on milestone payments.
- Roche Milestone: Monitor the progress of the EVT 101 Phase II study and the likelihood of Roche exercising the USD 65 million buy-back option.
- Revenue Mix: Assess the sustainability of revenue growth from discovery alliances versus the volatility of milestone and out-licensing income.
- Cost Structure: Confirm that R&D expenses remain near the EUR 10 million guidance level as proprietary programs are further de-risked or partnered.
- Auction Rate Securities: Review the valuation and liquidity status of the EUR 9.8 million holding in ARS, which are classified as available-for-sale but face market illiquidity.